PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33468831-8 2020 The patient started an immediate course of combination chemotherapy consisting of rituximab, cyclophosphamide, doxorubicin vincristine and prednisolone(R-CHOP)and no recurrence has been noted for 5 years and 10 months from first visit. Prednisolone 139-151 DNA damage inducible transcript 3 Homo sapiens 154-158 2601224-7 1989 Although 3 courses of combination chemotherapy with cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) were given, no remission was obtained. Prednisolone 99-111 DNA damage inducible transcript 3 Homo sapiens 113-117 6697295-4 1984 A few hours after initiation of chemotherapy with cyclophosphamide, Adriamycin (doxorubicin), vincristine, and prednisolone (CHOP regimen), the patient developed an acute ascending paralysis. Prednisolone 111-123 DNA damage inducible transcript 3 Homo sapiens 125-129 6191677-0 1983 [Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin"s lymphoma]. Prednisolone 58-70 DNA damage inducible transcript 3 Homo sapiens 72-76 2464185-5 1988 Therapeutic trials of CHOP-BLEO merit further assessment and the results should be compared to the baseline treatment using platinum and prednisolone. Prednisolone 137-149 DNA damage inducible transcript 3 Homo sapiens 22-26 3840280-2 1985 We have reported a case of diffuse, poorly differentiated lymphocytic lymphoma, stage IIIa, in a patient whose disease went into remission after she received six courses of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone). Prednisolone 235-247 DNA damage inducible transcript 3 Homo sapiens 173-177 32529585-0 2020 Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study. Prednisolone 10-22 DNA damage inducible transcript 3 Homo sapiens 37-41 32529585-1 2020 Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is one of the standard regimens for indolent B-cell non-Hodgkin"s lymphoma (NHL). Prednisolone 63-75 DNA damage inducible transcript 3 Homo sapiens 79-83 32915975-2 2020 Exposure to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) is likely to increase the risk of fracture, but evidence is lacking to define fracture incidence in this group. Prednisolone 79-91 DNA damage inducible transcript 3 Homo sapiens 14-18 30581162-2 2019 Addition of rituximab to a reduced dose (RD) of cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy might improve patient outcomes with an improved toxicity profile when provided to elderly patients with diffuse large B-cell lymphoma. Prednisolone 96-108 DNA damage inducible transcript 3 Homo sapiens 112-116 33093947-0 2020 ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. Prednisolone 96-108 DNA damage inducible transcript 3 Homo sapiens 112-116 33093947-3 2020 R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) is accepted as the international standard first-line regimen, but improvement in first line treatment is needed. Prednisolone 63-75 DNA damage inducible transcript 3 Homo sapiens 2-6 32643971-3 2020 For elderly patients, the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen is well tolerated, but it is an insufficient induction therapy for this group. Prednisolone 85-97 DNA damage inducible transcript 3 Homo sapiens 101-105 32349779-1 2020 BACKGROUND: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy is widely used in peripheral T cell lymphoma (PTCL). Prednisolone 60-72 DNA damage inducible transcript 3 Homo sapiens 74-78 32349779-1 2020 BACKGROUND: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy is widely used in peripheral T cell lymphoma (PTCL). Prednisolone 60-72 DNA damage inducible transcript 3 Homo sapiens 80-84 31723484-12 2019 Chemotherapy with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine (Oncovin ), and prednisolone (R-CHOP) was then resorted to which mitigated his symptoms. Prednisolone 102-114 DNA damage inducible transcript 3 Homo sapiens 118-122 31151970-7 2019 The patient received rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone (CHOP) immunochemotherapy with gradual but complete resolution of the erythroderma. Prednisolone 93-105 DNA damage inducible transcript 3 Homo sapiens 107-111 31832222-1 2019 Background: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen includes a high dose of prednisolone (100 mg/body), which exhibits an anticancer and antiemetic effect. Prednisolone 60-72 DNA damage inducible transcript 3 Homo sapiens 74-78 31832222-1 2019 Background: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen includes a high dose of prednisolone (100 mg/body), which exhibits an anticancer and antiemetic effect. Prednisolone 112-124 DNA damage inducible transcript 3 Homo sapiens 74-78 31222719-1 2019 Central nervous system (CNS) relapse following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) occurs in 2-5% of patents with diffuse large B-cell lymphoma (DLBCL). Prednisolone 110-122 DNA damage inducible transcript 3 Homo sapiens 49-53 30431571-4 2018 INTERVENTIONS AND OUTCOMES: Fortunately, the patient"s skin lesions subsided gradually after 3 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen. Prednisolone 153-165 DNA damage inducible transcript 3 Homo sapiens 167-171 30314526-2 2018 Rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) therapy represents the current standard therapy, achieving a rather dissatisfying outcome in approximately 30-40% of all cases. Prednisolone 77-89 DNA damage inducible transcript 3 Homo sapiens 93-97 30314526-6 2018 Treatment utilizing the gold standard rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) was performed, partly resulting in remission according to radiological follow-up. Prednisolone 115-127 DNA damage inducible transcript 3 Homo sapiens 131-135 29719411-2 2018 Patients with peripheral T-cell lymphoma (PTCL) generally have a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy; once relapse occurs, it is mostly regarded as an incurable disease. Prednisolone 146-158 DNA damage inducible transcript 3 Homo sapiens 160-164 30241515-4 2018 Cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisolone (CHOP) is the most common chemotherapy for non-Hodgkin lymphoma. Prednisolone 80-92 DNA damage inducible transcript 3 Homo sapiens 94-98 26449182-1 2017 The CHOP regimen consisting of cyclophosphamide, doxorubicin (DOX), vincristine and prednisolone has been the most used regimen for peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Prednisolone 84-96 DNA damage inducible transcript 3 Homo sapiens 4-8 29467881-1 2018 Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) has proven efficacy in clinical trials. Prednisolone 90-102 DNA damage inducible transcript 3 Homo sapiens 104-108 29618689-2 2018 Treatment with five cycles of doxorubicin, vincristine, cyclophosphamide, and prednisolone (CHOP) therapy was initiated, which resulted in insufficient improvement in anemia. Prednisolone 78-90 DNA damage inducible transcript 3 Homo sapiens 92-96 29333403-1 2017 Background: While cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is the most commonly used chemotherapeutic regimen for patients with peripheral T-cell lymphomas (PTCLs), elderly patients are more vulnerable to associated toxicities. Prednisolone 66-78 DNA damage inducible transcript 3 Homo sapiens 80-84 28725323-3 2017 Patients with an advanced stage B-cell malignant lymphoma are typically treated with a combination therapy of rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Prednisolone 172-184 DNA damage inducible transcript 3 Homo sapiens 188-192 27253186-20 2017 Treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine, and prednisolone) was initiated with very good clinical and biochemical response, yet only mild recovery of kidney function. Prednisolone 83-95 DNA damage inducible transcript 3 Homo sapiens 17-21 26834485-7 2016 CONCLUSION: It is generally believed that the regimen consisting of cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine, and prednisolone (CHOP) is also applicable to ALCL. Prednisolone 138-150 DNA damage inducible transcript 3 Homo sapiens 152-156 27928587-1 2017 Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy has been mostly applied to patients with untreated peripheral T cell lymphoma (PTCL). Prednisolone 48-60 DNA damage inducible transcript 3 Homo sapiens 62-66 27283030-4 2017 The patient was diagnosed with PEL-LL and treated with six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), which resulted in a complete remission. Prednisolone 132-144 DNA damage inducible transcript 3 Homo sapiens 148-152 29279550-7 2017 Patients with ALK-positive ALCL are usually treated with anthracycline-based regimens, such as combination cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOEP (CHOP plus etoposide), which provide a favorable prognosis, except in patients with multiple International Prognostic Index factors. Prednisolone 155-167 DNA damage inducible transcript 3 Homo sapiens 169-173 26990931-1 2016 BACKGROUND: Chemoimmunotherapy containing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is the standard treatment for diffuse large B-cell lymphoma (DLBCL). Prednisolone 101-113 DNA damage inducible transcript 3 Homo sapiens 117-121 26506947-5 2016 She was treated with two courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) for B-cell lymphoma, rituximab once every 3 weeks for five cycles, steroid pulse therapy, oral prednisolone, cyclosporin and high-dose i.v. Prednisolone 95-107 DNA damage inducible transcript 3 Homo sapiens 111-115 27530021-2 2016 After completion of one course of rituximab plus cyclophosphamide, pirarubicin, vincristine, and prednisolone (R-CHOP) chemotherapy, the patient developed lung abscess and sepsis caused by Streptococcus intermedius. Prednisolone 97-109 DNA damage inducible transcript 3 Homo sapiens 113-117 27736260-1 2017 Treatment of diffuse large B-cell lymphoma (DLBCL) with R-CHOP(-like) regimens include large cumulative doses of prednisolone. Prednisolone 113-125 DNA damage inducible transcript 3 Homo sapiens 58-62 28458356-1 2017 Management of constipation in patients receiving cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) or CHOP-like chemotherapy regimens is important for prevention of paralytic ileus. Prednisolone 96-108 DNA damage inducible transcript 3 Homo sapiens 110-114 28978846-6 2017 From recent prospective trials, conventional R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen, which is the current standard regimen for DLBCL, has been acknowledged as a well-established regimen for DLBCL. Prednisolone 112-124 DNA damage inducible transcript 3 Homo sapiens 47-51 27477167-0 2016 Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. Prednisolone 58-70 DNA damage inducible transcript 3 Homo sapiens 74-78 27073670-1 2016 The cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen is considered to be a standard treatment for non-Hodgkin"s lymphoma (NHL). Prednisolone 51-63 DNA damage inducible transcript 3 Homo sapiens 65-69 26764304-5 2016 His symptoms were improved after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy. Prednisolone 92-104 DNA damage inducible transcript 3 Homo sapiens 108-112 26370464-1 2015 BACKGROUND: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is an efficient treatment of non-Hodgkin"s lymphoma (NHL). Prednisolone 75-87 DNA damage inducible transcript 3 Homo sapiens 89-93 25177375-9 2014 CONCLUSIONS: In the current study, we identified the pre-treatment MTV measured by FDG-PET/CT as a potential predictor of survival in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), at least in Ann Arbor stage II and III disease. Prednisolone 226-238 DNA damage inducible transcript 3 Homo sapiens 242-246 25527602-7 2014 Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy reduced the size of the tumor, and the symptoms thereafter improved. Prednisolone 63-75 DNA damage inducible transcript 3 Homo sapiens 79-83 25316096-8 2014 Five patients received cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) chemotherapy. Prednisolone 70-82 DNA damage inducible transcript 3 Homo sapiens 84-88 25371707-5 2014 He received chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R CHOP) for eight cycles followed by radiation to the residual mass and achieved complete remission. Prednisolone 88-100 DNA damage inducible transcript 3 Homo sapiens 104-108 26376594-2 2015 We present a 64-year-old man who was treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemoimmunotherapy for mantle cell lymphoma and developed purulent meningitis, probably caused by Leuconostoc sp. Prednisolone 121-133 DNA damage inducible transcript 3 Homo sapiens 52-56 25430047-1 2015 This study aimed to clarify the association between the TP53 rs1625895 polymorphism and the efficiency of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy in 106 patients with diffuse large B cell lymphoma (DLBCL). Prednisolone 169-181 DNA damage inducible transcript 3 Homo sapiens 108-112 25459253-2 2014 We report the effect of a combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) for immunocompetent patients with PCNSL. Prednisolone 119-131 DNA damage inducible transcript 3 Homo sapiens 135-139 25337281-5 2014 The patient was treated with 6 courses of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone), which resulted in complete remission (CR). Prednisolone 104-116 DNA damage inducible transcript 3 Homo sapiens 42-46 24989286-9 2014 After 2 cycles of treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone(R-CHOP), the images of increasing metabolic activity in subcutaneous soft tissue gap disappeared, but the partial increasing metabolism focus could be observed in soft tissue of left knee hollow. Prednisolone 91-103 DNA damage inducible transcript 3 Homo sapiens 106-110 25197420-5 2014 The patient was treated with chemotherapeutic regimens-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone). Prednisolone 108-120 DNA damage inducible transcript 3 Homo sapiens 55-59 24428090-1 2013 OBJECTIVE: To determine the effectiveness and tolerability of the combination of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with the addition of etoposide (CHOEP-21) for newly diagnosed nodal peripheral T-cell lymphomas (PTCLs). Prednisolone 147-159 DNA damage inducible transcript 3 Homo sapiens 161-165 24395281-9 2014 Combination immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen improved both MALT lymphoma and PLE, whereas rituximab monotherapy was not successful. Prednisolone 95-107 DNA damage inducible transcript 3 Homo sapiens 111-115 23734653-4 2014 In 80 patients chemotherapy was initiated; 70 patients received rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP). Prednisolone 122-134 DNA damage inducible transcript 3 Homo sapiens 138-142 23053189-1 2013 R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma. Prednisolone 90-102 DNA damage inducible transcript 3 Homo sapiens 2-6 23452117-1 2013 Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) is regarded as the first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL), but it is often necessary to reduce the dose or prolong the intervals between doses. Prednisolone 71-83 DNA damage inducible transcript 3 Homo sapiens 87-91 23843497-4 2013 We also evaluated the influence of HLA polymorphisms on survival in those patients treated with curative intention using cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like regimen without (n = 64, 26%) or with (n = 153, 61%) rituximab. Prednisolone 169-181 DNA damage inducible transcript 3 Homo sapiens 183-187 23615461-1 2013 BACKGROUND: Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. Prednisolone 103-115 DNA damage inducible transcript 3 Homo sapiens 117-121 23615461-1 2013 BACKGROUND: Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. Prednisolone 103-115 DNA damage inducible transcript 3 Homo sapiens 236-240 23318862-5 2013 After undergoing rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) therapy, the patient was successfully treated with allogeneic hematopoietic transplantation, and no relapse was observed for three years. Prednisolone 75-87 DNA damage inducible transcript 3 Homo sapiens 91-95 23267908-5 2012 The malignant lymphoma patient was treated by cyclophosphamide+doxorubicin+vincristine+prednisolone(CHOP) with rituximab. Prednisolone 87-99 DNA damage inducible transcript 3 Homo sapiens 100-104 22739576-3 2012 Two hundred sixty-three patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were enrolled to this prospective cohort study, and their QoL was evaluated. Prednisolone 105-117 DNA damage inducible transcript 3 Homo sapiens 121-125 22752193-1 2012 The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) plus rituximab is the standard treatment for patients with primary gastric diffuse large B cell lymphoma (DLBCL). Prednisolone 82-94 DNA damage inducible transcript 3 Homo sapiens 96-100 23267962-13 2012 Cyclophosphamide+doxorubicin+vincristine+prednisolone(CHOP) with rituximab therapy was performed. Prednisolone 41-53 DNA damage inducible transcript 3 Homo sapiens 54-58 21181164-8 2011 Four patients received cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP)-like chemotherapy, and their median survival was 13 months. Prednisolone 70-82 DNA damage inducible transcript 3 Homo sapiens 84-88 22587388-1 2012 Rituximab (R) plus doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP) chemotherapy (R-CHOP) is widely accepted as standard care for diffuse large B-cell lymphoma (DLBCL) patients. Prednisolone 67-79 DNA damage inducible transcript 3 Homo sapiens 81-85 22587388-1 2012 Rituximab (R) plus doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP) chemotherapy (R-CHOP) is widely accepted as standard care for diffuse large B-cell lymphoma (DLBCL) patients. Prednisolone 67-79 DNA damage inducible transcript 3 Homo sapiens 103-107 23323070-8 2012 The association of this antibody to the cyclophosphamide, hydroxydaunorubicin, oncovin and prednisolone (CHOP) regimen has increased overall survival of diffuse large B-Cell lymphoma and follicular lymphoma patients by 20%. Prednisolone 91-103 DNA damage inducible transcript 3 Homo sapiens 105-109 22864129-5 2012 Combination chemotherapy composed of cyclophosphamide, vincristine, doxorubicin and prednisolone (CHOP) was effective for polyneuropathy as well as for lymphoma. Prednisolone 84-96 DNA damage inducible transcript 3 Homo sapiens 98-102 22259636-5 2011 The patient was treated using cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP), and achieved complete response (CR) at the first response assessment conducted after 3 CHOP cycles. Prednisolone 77-89 DNA damage inducible transcript 3 Homo sapiens 91-95 21148334-6 2011 When rituximab was used with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP), there was no improvement of the outcomes in patients treated with primary surgical resection. Prednisolone 77-89 DNA damage inducible transcript 3 Homo sapiens 91-95 21944785-4 2011 Chemotherapy in the form of R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, Oncovin and prednisolone) is considered to be the first line of treatment for these lymphomas. Prednisolone 99-111 DNA damage inducible transcript 3 Homo sapiens 31-35 22454706-5 2011 He received chemotherapy with CHOP regimen (cyclophosphamide, adriamycin, vincristine and prednisolone) resulting in reduction in lesion size leaving a phthysical eyeball and a ptotic lid. Prednisolone 90-102 DNA damage inducible transcript 3 Homo sapiens 30-34 18408447-4 2008 The patient was treated with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP). Prednisolone 90-102 DNA damage inducible transcript 3 Homo sapiens 104-108 18583880-1 2008 The objective of the current study was to investigate the treatment outcomes for the use of cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) chemotherapy in adult patients with hemophagocytic lymphohistiocytosis (HLH). Prednisolone 139-151 DNA damage inducible transcript 3 Homo sapiens 153-157 20177729-8 2010 High-dose steroid therapy followed by six courses of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) therapy improved his symptoms. Prednisolone 101-113 DNA damage inducible transcript 3 Homo sapiens 115-119 20367135-2 2010 PCP is uncommon with classical (3-weekly) R-CHOP, but the risk may be higher with biweekly R-CHOP (R-CHOP-14) due to the increased frequency of prednisolone pulses. Prednisolone 144-156 DNA damage inducible transcript 3 Homo sapiens 93-97 20367135-2 2010 PCP is uncommon with classical (3-weekly) R-CHOP, but the risk may be higher with biweekly R-CHOP (R-CHOP-14) due to the increased frequency of prednisolone pulses. Prednisolone 144-156 DNA damage inducible transcript 3 Homo sapiens 93-97 19861288-1 2009 Treatment with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been considered as the standard therapy for diffuse large B-cell lymphoma (DLBCL) for more than 20 years. Prednisolone 62-74 DNA damage inducible transcript 3 Homo sapiens 76-80 19496708-2 2009 Association of rituximab with chemotherapy (mostly the cyclophosphamide, doxorubicin, vincristine and prednisolone [CHOP] regimen) in diffuse large B-cell lymphoma (DLBCL) represents an extraordinary revolution in the prognosis of DLBCL, and is the new standard of therapy in elderly and young, low-risk patients. Prednisolone 102-114 DNA damage inducible transcript 3 Homo sapiens 116-120 19204436-5 2009 There was significant improvement in response to the first 4 cycles of CHOP chemotherapy (consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone) instituted, but then there were features of relapse. Prednisolone 151-163 DNA damage inducible transcript 3 Homo sapiens 71-75 18269578-7 2008 MDM2 amplification and cyclophosphamide doxorubicin hydrochloride (adriamycin), vincristine and prednisolone (CHOP) translocation was studied in seven cases by fluorescence in situ hybridization. Prednisolone 96-108 DNA damage inducible transcript 3 Homo sapiens 110-114 18306483-2 2008 Shortness of breath developed following the 5th course of Rituximab-CHOP chemotherapy (cyclophosphamide, Vincristine, Doxorubicin, Prednisolone). Prednisolone 131-143 DNA damage inducible transcript 3 Homo sapiens 68-72 18670848-8 2008 The patient received three courses of combination chemotherapy [cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)], and there was no evidence of recurrence 45 months after the surgery. Prednisolone 111-123 DNA damage inducible transcript 3 Homo sapiens 125-129 18226581-1 2008 BACKGROUND: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is used to treat patients with non-Hodgkin lymphoma. Prednisolone 60-72 DNA damage inducible transcript 3 Homo sapiens 74-78 17957940-9 2007 At this time, he was treated with cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) with whole brain irradiation. Prednisolone 81-93 DNA damage inducible transcript 3 Homo sapiens 95-99 17530014-5 2007 A combination of rituximab plus chemotherapy, rituximab+cyclophosphamide+doxorubicin+vincristine+prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL. Prednisolone 97-109 DNA damage inducible transcript 3 Homo sapiens 113-117 17939339-5 2007 A CT scan performed following three cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) showed that the mass had nearly disappeared. Prednisolone 112-124 DNA damage inducible transcript 3 Homo sapiens 126-130 17094093-5 2007 She received two cycles of cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP) that started 10 weeks after the initiation of antiretroviral therapy. Prednisolone 75-87 DNA damage inducible transcript 3 Homo sapiens 89-93 16550755-9 2006 Despite treatment with rituximab and CHOP (prednisolone, doxorubicin, vincristine, cyclophosphamide) for 3 cycles at 1-month intervals, the renal dysfunction did not change. Prednisolone 43-55 DNA damage inducible transcript 3 Homo sapiens 37-41 17220687-3 2007 Lymphoma enlarged even after the fourth courses of chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). Prednisolone 126-138 DNA damage inducible transcript 3 Homo sapiens 140-144 17085516-4 2006 The management of patients with AIDS-related NHL with either infusional chemotherapy or CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine and prednisolone) achieves response and survival rates approaching those observed in the general population. Prednisolone 155-167 DNA damage inducible transcript 3 Homo sapiens 88-92 10674903-1 2000 A regimen which incorporates cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) is the standard treatment for patients with non-Hodgkin"s lymphoma (NHL), but it has not been effective in patients with aggressive NHL who are at high risk. Prednisolone 76-88 DNA damage inducible transcript 3 Homo sapiens 90-94 16430465-2 2006 The lymphoma responded to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) chemotherapy. Prednisolone 84-96 DNA damage inducible transcript 3 Homo sapiens 100-104 16307545-3 2005 Complete remission of CLL with resolution of the osteolytic lesion was achieved with rituximab and cyclophosphamide, adriamycin, oncovin and prednisolone [CHOP (R-CHOP)] combination chemotherapy. Prednisolone 141-153 DNA damage inducible transcript 3 Homo sapiens 155-159 15728147-4 2005 Chemotherapy consisted of adriamycin, cyclophosphamide, vincristine and prednisolone (CHOP). Prednisolone 72-84 DNA damage inducible transcript 3 Homo sapiens 86-90 21289975-8 2004 The patient received chemotherapy with 2 courses of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP). Prednisolone 99-111 DNA damage inducible transcript 3 Homo sapiens 113-117 15005254-8 2004 The patient was treated with chemotherapy by cyclophosphamide, hydroxydoxorubicin, vincristine and prednisolone (CHOP), however, it was ineffective, and the patient died of hemorrhage from the lymphoma involvement of the intestine 5 months after the onset of disease. Prednisolone 99-111 DNA damage inducible transcript 3 Homo sapiens 113-117 12955576-4 2003 A recent European phase III study in elderly patients with untreated diffuse large B-cell lymphoma suggested that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy is superior to CHOP chemotherapy alone in terms of complete response rate and event-free and overall survivals. Prednisolone 177-189 DNA damage inducible transcript 3 Homo sapiens 191-195 12955576-4 2003 A recent European phase III study in elderly patients with untreated diffuse large B-cell lymphoma suggested that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy is superior to CHOP chemotherapy alone in terms of complete response rate and event-free and overall survivals. Prednisolone 177-189 DNA damage inducible transcript 3 Homo sapiens 225-229 11276342-6 2001 The patient was treated with combination chemotherapy, including cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP), which resulted in complete clinical remission after two courses. Prednisolone 112-124 DNA damage inducible transcript 3 Homo sapiens 126-130 1630019-6 1992 The patient was treated with the CHOP regimen (doxorubicin, cyclophosphamide, vincristine and prednisolone), which achieved complete remission. Prednisolone 94-106 DNA damage inducible transcript 3 Homo sapiens 33-37 9649147-3 1998 CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) only slightly induces pulmonary toxicity. Prednisolone 61-73 DNA damage inducible transcript 3 Homo sapiens 0-4 9530358-1 1998 A pilot study of high-dose biweekly cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) chemotherapy with granulocyte colony-stimulating factor support was carried out at 11 centers. Prednisolone 83-95 DNA damage inducible transcript 3 Homo sapiens 97-101 9409065-1 1997 Cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisolone (CHOP) has for many years been the standard chemotherapeutic regimen for patients with aggressive non-Hodgkin"s lymphoma. Prednisolone 58-70 DNA damage inducible transcript 3 Homo sapiens 72-76 9272145-5 1997 One is a randomized phase II trial of dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisolone (high CHOP) versus shortened CHOP (biweekly CHOP) with prophylactic use of granulocyte colony-stimulating factor. Prednisolone 101-113 DNA damage inducible transcript 3 Homo sapiens 120-124 8688344-1 1996 A combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been a standard therapy for histologically aggressive non-Hodgkin"s lymphomas for over 20 years, but several newer regimens, referred to as second or third generation, have been reported to give improved results in single-centre studies. Prednisolone 64-76 DNA damage inducible transcript 3 Homo sapiens 78-82 7796361-6 1995 All patients were treated with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) and adjuvant radiotherapy. Prednisolone 78-90 DNA damage inducible transcript 3 Homo sapiens 92-96 8469201-6 1993 TREATMENT AND OUTCOME: After initial response to CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisolone), she relapsed and died with central nervous system involvement eight months after the initial diagnosis. Prednisolone 112-124 DNA damage inducible transcript 3 Homo sapiens 49-53 10407583-2 1999 She received 6 courses of chemotherapy including cyclophosphamide, doxorubicin, vincristine, and prednisolone every two weeks (biweekly CHOP), and was considered to be in partial remission. Prednisolone 97-109 DNA damage inducible transcript 3 Homo sapiens 136-140 8629263-5 1996 The CHOP-regime, consisting of doxorubicin, cyclophosphamide, oncovin and prednisolon, is the standard therapy that should be given outside of clinical trials. Prednisolone 74-85 DNA damage inducible transcript 3 Homo sapiens 4-8 8558202-17 1996 These data are the basis for a randomized trial to compare cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with CEOP/IMVP-Dexa. Prednisolone 107-119 DNA damage inducible transcript 3 Homo sapiens 121-125 8369658-11 1993 Our successful treatment is radiation therapy combined with six courses of CHOP chemotherapy (cyclophosphamide, adriamycin, vincristine, prednisolone). Prednisolone 137-149 DNA damage inducible transcript 3 Homo sapiens 75-79 2246824-6 1990 After chemotherapy using adriamycin, cyclophosphamide, vincristine, and prednisolone (CHOP), lymphadenopathy and splenomegaly reduced and lymphoid blasts disappeared from the blood and bone marrow. Prednisolone 72-84 DNA damage inducible transcript 3 Homo sapiens 86-90 34895738-7 2021 CASE SUMMARY: An 81-year-old female patient received her first cycle of R-CHOP (rituximab, cyclophosphamide, vincristine, and prednisolone) treatment after being diagnosed with high- grade B-cell lymphoma. Prednisolone 126-138 DNA damage inducible transcript 3 Homo sapiens 74-78 34990525-1 2021 Purpose: Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Prednisolone 225-237 DNA damage inducible transcript 3 Homo sapiens 241-245 2317752-4 1990 Continuous CHOP protocol consists of initial 8 weeks of intensive chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone, followed by local/cranial radiotherapy and maintenance therapy. Prednisolone 132-144 DNA damage inducible transcript 3 Homo sapiens 11-15 34610523-9 2021 The patient was treated successfully with cyclophosphamide, doxorubicin, vincristine and prednisolone (mini-CHOP regimen). Prednisolone 89-101 DNA damage inducible transcript 3 Homo sapiens 108-112 34745610-0 2021 Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. Prednisolone 181-193 DNA damage inducible transcript 3 Homo sapiens 209-213 34745610-1 2021 Objectives: A diverse intratumoral T-cell receptor (TCR) repertoire is associated with improved survival in diffuse large B-cell lymphoma (DLBCL) treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. Prednisolone 198-210 DNA damage inducible transcript 3 Homo sapiens 226-230 34661507-2 2021 Therefore, we evaluated 32 patients who received rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) therapy for B-cell malignant lymphoma by analysing the changes in atherosclerosis. Prednisolone 107-119 DNA damage inducible transcript 3 Homo sapiens 123-127 34765356-4 2021 We report a case of a 65-year-old man who presented with acutely worsening dyspnoea and stridor following his fifth cycle of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy for hematological malignancy. Prednisolone 184-196 DNA damage inducible transcript 3 Homo sapiens 200-204 35210509-8 2022 Seventy-two patients were treated with a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP-like) regimen, and six were treated with low-toxicity regimens. Prednisolone 89-101 DNA damage inducible transcript 3 Homo sapiens 103-107 35297262-13 2022 The patient received treatment with mini-CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone) plus rituximab with partial response after the third cycle. Prednisolone 108-120 DNA damage inducible transcript 3 Homo sapiens 41-45 35478137-2 2022 To precisely monitor ADRs, we developed a medication instruction sheet (MIS) for patients who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) combination therapy for non-Hodgkin"s lymphoma (NHL). Prednisolone 162-174 DNA damage inducible transcript 3 Homo sapiens 178-182 35545831-9 2022 The patient received chemotherapy with cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP protocol) for 3 cycles. Prednisolone 87-99 DNA damage inducible transcript 3 Homo sapiens 101-105 35220927-1 2022 Bendamustine plus rituximab (BR) and rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) have been shown to be effective in the treatment of indolent B-cell lymphomas (iBCL). Prednisolone 95-107 DNA damage inducible transcript 3 Homo sapiens 111-115 35218445-8 2022 Combination treatment with prednisolone, a component of CHOP and CVP, was found to enhance ADCC sensitivity of RL cells and resistant clones and to significantly suppress tumor growth in xenograft models. Prednisolone 27-39 DNA damage inducible transcript 3 Homo sapiens 56-60 35044836-1 2022 PURPOSE: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) represents the standard of care for first-line treatment of diffuse large B-cell lymphoma (DLBCL). Prednisolone 72-84 DNA damage inducible transcript 3 Homo sapiens 88-92 34622970-10 2022 After five cycles of cyclophosphamide + doxorubicin + vincristine + prednisolone (CHOP) chemotherapy, the patient achieved complete remission. Prednisolone 68-80 DNA damage inducible transcript 3 Homo sapiens 82-86